You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

 

480 Results
Senior chercheuse, Unité des soins de cancérologie chez les peuples autochtones, Soins aigus et hospitaliers, Santé Ontario Chercheuse...
Senior Scientist, Acute and Hospital-Based Care, Ontario Health Senior Scientistanna.chiarelli@ontariohealth.ca
Chercheuse principale, Soins aigus et hospitaliers, Santé Ontario Chercheuse principaleanna.chiarelli@ontariohealth.ca
Scientist, Cancer Screening – Program Design, Acute and Hospital-Based Care, Ontario Health Behavioural Scientistdiego.llovet@ontariohealth.ca
Chercheur, Cancer Screening – Program Design, Soins aigus et hospitaliers, Santé Ontario Spécialiste des sciences du comportementdiego.llovet@...
Drug
Other Name(s): Tecentriq™
Mar 2024
Drug
Other Name(s): Imfinzi®
Apr 2024
Drug
Other Name(s): Bavencio™
Jan 2025
Drug
Other Name(s): Erleada®
Jan 2025
Regimen
Cancer Type:
Skin, 
Merkel Cell
Intent: Palliative
Funding:
New Drug Funding Program
    Avelumab - Metastatic Merkel Cell Carcinoma
Jan 2025
Regimen
Cancer Type:
Genitourinary, 
Prostate
Intent: Palliative
Funding:
Exceptional Access Program
    apalutamide - For the treatment of non-metastatic castration resistant prostate cancer (nmCRPC), based on criteria
Exceptional Access Program
    apalutamide - For the treatment of metastatic castration sensitive prostate cancer (mCSPC), based on criteria
Jan 2025
Regimen
Cancer Type:
Genitourinary, 
Bladder / Urothelial
Intent: Palliative
Funding:
New Drug Funding Program
    Avelumab - Maintenance Treatment for Unresectable Locally Advanced or Metastatic Urothelial Carcinoma
Jan 2025

Pages